Karl Anderson

Program Director of Clinical Science in Preventive Medicine & Community Health · University of Texas Medical Branch Hospitals

Credentials: · · · ·

History

Effect of Oral Cimetidine in the Protoporphyrias (IND 153247 Submitted 9/2/2020)
Food and Drug Administration · R01
PI · $1.6M · Massachusetts General Hospital
2021–2026
Phase 2 Study of Hemin for Treatment and Prevention of Porphyria Attacks
Food and Drug Administration · R01
Contact PI · $1.3M · University of Texas Med Br Galveston
2013–2021
Hydroxychloroquine vs Phlebotomy for PCT
Food and Drug Administration · R01
Contact PI · $928.6K · University of Texas Med Br Galveston
2005–2010
Genetic Susceptibility Factors in Porphyria Cutanea Tarda (PCT)
National Institute of Diabetes and Digestive and Kidney Diseases · R21
Contact PI · $443.6K · University of Texas Med Br Galveston
2006–2010

Effect of Oral Cimetidine in the Protoporphyrias
Principal investigator · Completed · Phase 2
Amy K. Dickey, M.D.
2022–2025
Panhematin for Prevention of Acute Attacks of Porphyria
Principal investigator · Terminated · Phase 2
The University of Texas Medical Branch, Galveston
2015–2023
Acute Porphyria Biomarkers for Disease Activity
Principal investigator · Active not recruiting
The University of Texas Medical Branch, Galveston
2014–2026
Clinical Diagnosis of Acute Porphyria
Principal investigator · Completed
University of California, San Francisco
2011–2018